Literature DB >> 1104900

Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study.

W W Scott, D E Johnson, J E Schmidt, R P Gibbons, G R Prout, J R Joiner, J Saroff, G P Murphy.   

Abstract

The National Prostatic Cancer Project has randomized this study for endocrine-resistant prostatic cancer patients for treatment with standard hormonal or other therapies compared to 5-fluorouracil and cyclophosphamide. Both agents were found at the probability level of 0.05 to have a significant advantage over standard treatment in terms of objective response, subjective improvement and minimal toxicity. Additional chemotherapy protocols are currently under way. This randomized trial is the first report of such a national study completed to date. We are much encouraged by this program and believe that additional agents now under consideration will provide additionally encouraging results.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1104900     DOI: 10.1016/s0022-5347(17)67172-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 2.  Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.

Authors:  Andrew J Armstrong; Michael A Carducci
Journal:  Curr Oncol Rep       Date:  2005-05       Impact factor: 5.075

3.  Treatment of an Nb-Pr-A.I.-3 (autonomous) tumor with combination chemotherapy.

Authors:  J R Drago; T Worgul
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 4.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.

Authors:  D Singh; J H Doroshow; L Leong; K Margolin; S Akman; J Raschko; G Somlo; R Morgan; J Harrison; J Cho
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.

Authors:  H Fuse; Y Muraishi; Y Fujishiro; T Katayama
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.